(NP (NP (DT The) (JJ impaired) (NN transcription) (NN factor) (NN AP-1) (NN DNA) (NN binding) (NN activity)) (PP (IN in) (NP (NP (NNS lymphocytes)) (VP (VBN derived) (NP (-NONE- *)) (PP (IN from) (NP (NP (NNS subjects)) (PP (IN with) (NP (NP (DT some) (NNS symptoms)) (PP (IN of) (NP (JJ premature) (NN aging)))))))))) (. .))
(S (NP-SBJ (NP (DT The) (NN study)) (PP (IN of) (NP (NP (JJ human) (NNS disorders)) (VP (VBN known) (NP (-NONE- *)) (PP (IN as) (NP (JJ premature) (NN aging) (NNS syndromes))))))) (VP (MD may) (VP (VB provide) (NP (NP (NN insight)) (PP (IN into) (NP (NP (DT the) (NNS mechanisms)) (PP (IN of) (NP (JJ cellular) (NN senescence)))))))) (. .))
(S (NP-SBJ (NP (DT The) (JJ main) (NN feature)) (PP (IN of) (NP (NP (JJ cellular) (NN senescence)) (ADVP (FW in) (FW vitro))))) (VP (VBZ is) (NP-PRD (NP (NN cessation)) (PP (IN of) (NP (NN cell) (NN proliferation))))) (. .))
(S (NP-SBJ-COOD-72 (NP (NP (NN Down) (NN syndrome)) (PRN (-LRB- -LRB-) (NP (NN DS)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ neuronal) (NN ceroid-lypofuscinosis)) (PRN (-LRB- -LRB-) (NP (NN NCL)) (-RRB- -RRB-)))) (VP (VBP are) (VP (ADVP (RB clinically)) (VBN characterized) (NP (-NONE- *-72)) (PP (IN by) (NP-LGS (NP (DT the) (JJ premature) (NN onset)) (PP (IN of) (NP (NP (JJ numerous) (NNS features)) (VP (ADVP (RB normally)) (VBN associated) (NP (-NONE- *)) (PP (IN with) (NP (JJ human) (NN aging)))))))))) (. .))
(S (NP-SBJ (NP (ADJP (NP (NN Phytohemagglutinin)) (JJ stimulated)) (NNS lymphocytes)) (VP (VBN derived) (NP (-NONE- *)) (PP (IN from) (NP (NN DS) (NNS subjects))))) (VP (VBD showed) (NP (DT a) (ADJP (RB statistically) (JJ significant)) (VBN diminished) (NN proliferation) (NN capacity)) (PP (IN in) (NN comparison) (IN with) (NP (NP (NNS lymphocytes)) (VP (VBN derived) (NP (-NONE- *)) (PP (IN from) (NP (UCP-COOD (NP (NN NCL)) (CC and) (ADJP (JJ healthy))) (NNS individuals))))))) (. .))
(S (NP-SBJ-73 (PRP We)) (VP (VBD demonstrated) (, ,) (PP (IN by) (S (NP-SBJ (-NONE- *-73)) (VP (VBG applying) (NP (DT the) (JJ electrophoretic) (NN mobility) (NN shift) (NN assay))))) (, ,) (NP-COOD (NP (NP (ADJP-114 (RB slightly) (JJ impaired)) (NN AP-1) (NN DNA) (NN binding) (NN activity)) (PP-113 (IN in) (NP (NN NCL) (NNS lymphocytes)))) (CC and) (NP (ADJP=114 (JJ strong)) (PP=113 (IN in) (NP (NN DS) (NNS ones)))))) (. .))
(S (NP-SBJ (PRP$ Our) (NNS results)) (VP (VBD showed) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (JJ same) (JJ molecular) (NNS mechanisms)) (PP (IN of) (NP (NN proliferation) (NN cessation)))) (VP (MD could) (VP (VB exist) (PP-COOD (PP (IN in) (NP (NP (NNS fibroblasts)) (VP (VBN characterized) (NP (-NONE- *)) (PP (IN by) (NP-LGS (JJ replicative) (NN senescence)))))) (CC and) (PP (IN in) (NP (NP (NNS lymphocytes)) (VP (VBN derived) (NP (-NONE- *)) (PP (IN from) (NP (NP (NNS individuals)) (PP (IN with) (NP (NP (JJ premature) (NN aging) (NNS syndromes)) (PRN (-LRB- -LRB-) (NP (NN Down)) (-RRB- -RRB-))))))))))))))) (. .))
